AGEN

AGEN 1777 (anti-TIGIT)

Cancer

IND Submission

Exp Date

December 2020 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: AGEN1777 for Cancer IND Submission


WHAT IS THE NEXT CATALYST EVENT?

  • IND Submission

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?  

  • December 2020 (Est)

PRIOR DATA 

PRESS RELEASE 


MECHANISM OF ACTION

  • AGEN1777 with expected IND filing by year end – a first-in-class TIGIT bispecific which targets a major inhibitory receptor expressed on T and NK cells to improve anti-tumor activity.

  • TIGIT is a negative regulator of innate and adaptive immune responses.

  • IND filing is expected by end of 2020

Updated by MV

AGEN, AGEN1777, cancer, anti-TIGIT

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

KPTI - Karyopharm Announces Ph...

Summary: Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Placebo; Hazard Ratio of 0.70, p=0.023 Positive Piv...

Will ATNX stock price pop if O...

ATNX's oraxol has shown some pretty good data in metastatic breast cancer. And oral paclitaxel vs. IV paclitaxel seems to have some patient convenience advantage. However, the stock has not responded ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon